ライフサイエンスコーパス: canagliflozin

1 ned largely unchanged in those randomized to canagliflozin.

2 the majority of amputations were observed on canagliflozin.

3 lozin, with 5% for empagliflozin, and 1% for canagliflozin.

4 ted by the synthesis of the SGLT2 inhibitor, canagliflozin.

5 lied to the synthesis of the alpha-anomer of canagliflozin.

6 umin-to-creatinine ratio decreased more with canagliflozin 100 mg (31.7%; 95% CI, 8.6% to 48.9%; P=0.

7 ed at least one dose of glimepiride (n=482), canagliflozin 100 mg (n=483), or canagliflozin 300 mg (n

8 In the canagliflozin 100 mg and 300 mg groups versus the glimep

9 the glimepiride group versus 24 (5%) in the canagliflozin 100 mg group and 26 (5%) in the 300 mg gro

10 tive voice or web response system to receive canagliflozin 100 mg or 300 mg, or glimepiride (up-titra

11 For lowering of HbA1c at 52 weeks, canagliflozin 100 mg was non-inferior to glimepiride (le

12 Glimepiride, canagliflozin 100 mg, and canagliflozin 300 mg groups ha

13 n and randomly assigned to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiri

14 Patients receiving glimepiride, canagliflozin 100 mg, or canagliflozin 300 mg had reduct

15 In 666 T2DM patients randomized to receive canagliflozin 100 or 300 mg or placebo, the study assess

16 In conclusion, canagliflozin 100 or 300 mg/d, compared with glimepiride

17 ted by the synthesis of the SGLT2 inhibitor, canagliflozin (1a), from commercially available 10 in on

18 mg (31.7%; 95% CI, 8.6% to 48.9%; P=0.01) or canagliflozin 300 mg (49.3%; 95% CI, 31.9% to 62.2%; P<0

19 de (n=482), canagliflozin 100 mg (n=483), or canagliflozin 300 mg (n=485).

20 Glimepiride, canagliflozin 100 mg, and canagliflozin 300 mg groups had eGFR declines of 3.3 ml/

21 eiving glimepiride, canagliflozin 100 mg, or canagliflozin 300 mg had reductions in HbA1c of 0.81%, 0

22 fference -0.01% [95% CI -0.11 to 0.09]), and canagliflozin 300 mg was superior to glimepiride (-0.12%

23 d to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride uptitrated to 6-8 m

24 Oral administration of canagliflozin activated AMPK in mouse liver, although no

25 This study suggests that canagliflozin, aliskiren, and darunavir may induce profo

26 We now report that canagliflozin also activates AMPK, an effect also seen w

27 Although canagliflozin also inhibited cellular glucose uptake ind

28 Canagliflozin also inhibited lipid synthesis, an effect

29 nergy calculations and inhibition assays for canagliflozin, an antidiabetic agent verified its effect

30 We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in p

31 Serum sST2 was unchanged with canagliflozin and placebo over 104 weeks.

32 ence in median percent change between pooled canagliflozin and placebo were -15.0%, -16.1%, and -26.8

33 s for these transporters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of i

34 pecific inhibitors, including dapagliflozin, canagliflozin, and empagliflozin, increase glucose excre

35 including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic

36 These findings support the use of canagliflozin as a viable treatment option for patients

37 ypertension and diabetes, aliskiren-based or canagliflozin-based drug design against HIV-1 PR may eli

38 The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) randomly

39 The CANVAS trial (Canagliflozin Cardiovascular Assessment Study) subsequen

40 hort, the primary end point was reduced with canagliflozin compared with placebo (26.9 versus 31.5/10

41 AMPK activation occurred at canagliflozin concentrations measured in human plasma in

42 y weight, BP, and albuminuria, implying that canagliflozin confers renoprotection.

43 Canagliflozin, dapagliflozin, and empagliflozin accounte

44 Canagliflozin, dapagliflozin, and empagliflozin, all rec

45 We determined whether canagliflozin decreases albuminuria and reduces renal fu

46 dium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight, BP, and albu

47 Compared with placebo, treatment with canagliflozin delayed the rise in serum NT-proBNP and hs

48 und of the 95% CI for the difference of each canagliflozin dose versus glimepiride of less than 0.0%.

49 ty margin of 0.3% for the comparison of each canagliflozin dose with glimepiride.

50 , urinary tract infections (31 [6%] for both canagliflozin doses vs 22 [5%]), and osmotic diuresis-re

51 he previously reported risks associated with canagliflozin except for an increased risk of amputation

52 Because of the disproportionate canagliflozin exposure in the database, the majority of

53 , 0.4 to 1.4), respectively (P<0.01 for each canagliflozin group versus glimepiride).

54 ardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events

55 orter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular mo

56 or canagliflozin-renin; K(i,exp)= 628 nM for canagliflozin-HIV-1 PR).

57 provide further insights into the effects of canagliflozin in these patient populations.

58 Canagliflozin is a sodium glucose cotransporter 2 inhibi

59 Background Canagliflozin is a sodium-glucose cotransporter 2 inhibi

60 years in patients with type 2 diabetes, and canagliflozin may confer renoprotective effects independ

61 of this study was to examine the effects of canagliflozin on cardiovascular biomarkers in older pati

62 We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outco

63 each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of

64 articipants with type 2 diabetes mellitus to canagliflozin or placebo.

65 Canagliflozin provides greater HbA1c reduction than does

66 Canagliflozin reduced cardiovascular and renal outcomes

67 oteins (DeltaG(pred) = -9.1 kcal mol(-1) for canagliflozin-renin; K(i,exp)= 628 nM for canagliflozin-

68 e rate of the primary outcome was lower with canagliflozin than with placebo (occurring in 26.9 vs. 3

69 ta suggest a potential additional benefit of canagliflozin therapy compared with other SGLT2 inhibito

70 ctin-3 modestly increased from baseline with canagliflozin versus placebo, with significant differenc

71 nt, the results showed a possible benefit of canagliflozin with respect to the progression of albumin